---
schema_version: "secwatch.filing_event.v1"
accession: "0001069530-22-000061"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2022-11-22T23:59:59+00:00"
generated_at: "2026-06-21T13:48:32.715111+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences closes $50M registered direct offering of 1.67M shares at $30/share

## Summary
- Gross proceeds ~$50M from 1,666,667 shares at $30; net proceeds ~$47.3M after fees.
- H.C. Wainwright acted as exclusive placement agent; JonesTrading and Perella Weinberg as advisors.
- Proceeds to fund working capital and development of simufilam, its lead Alzheimer's candidate.
- Offering closed Nov. 22, 2022; shares sold under existing shelf registration statement.
- 90-day lock-up on company share sales; prohibition on variable-rate transactions for 90 days.

## SEC filing metadata
- accession: 0001069530-22-000061
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2022-11-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000106953022000061/0001069530-22-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000106953022000061/sava-20221118x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001069530-22-000061
- JSON: https://secwatch.observer/filing/0001069530-22-000061.json
- Plain text: https://secwatch.observer/filing/0001069530-22-000061.txt

## Key facts
- Material Agreements
  FILANA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain investors valued at approximately $50 million (effective 2022-11-18).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain investors
  - Value: approximately $50 million
  - Effective: 2022-11-18
  source text: On November 18, 2022, Cassava Sciences, Inc. (the “ Company ” ) entered into a Securities Purchase Agreement (the “ Agreement ” ) with certain investors (each, including its successors and assigns, a “ Purchaser, ” and collectively the “ Purchasers ” ), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the “ Offering ”) 1,666,667 shares (the “ Shares ” ) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ” ), at an offering price of $30.00 per share, for gross proceeds of approximately $50 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000106953022000061/0001069530-22-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.